It was reported that both serum ALT and AST were attenuated by PCSK9 inhibition therapy in alcoholic liver disease and non-alcoholic fatty liver disease (NAFLD) (46, 47), but no previous studies reported the attenuation of aminotransferase by PCSK9 inhibitors in tumor treatment-related hepatotoxicity. This evidence concerns the gene PCSK9 and metabolic dysfunction-associated steatotic liver disease.